"000278654600012" . "0049-3848" . "Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention" . . "Thrombosis Research" . . "6"^^ . "Gregor, Zden\u011Bk" . "254534" . . . "1" . "126" . . "RIV/00216224:14110/10:00046981" . . "[9EE244E4ACDF]" . . . . . . "Dvo\u0159\u00E1k, Martin" . "Introduction: The aim of the study was to compare the efficacy of standard unfractionated heparin (UFH) and low-molecular weight heparins (LMWH's). Methods: We modified a previously published rabbit model of arterial thrombosis prevention to compare UFH and two different doses of two LMWH fragments - nadroparin and enoxaparin. Thrombosis was triggered by vessel wall injury and critical stenosis. Blood flow monitored by a flow probe. The primary endpoints were: cumulative flow, time to occlusion and residual clot weight. Thirty six animals were split into 6 groups. Control groups were given saline or UFH and four more groups were used to compare LMWH's at 2 different doses. Results: In our study, all treatments were superior to the saline control group. UFH was inferior to both LMWH's for all primary endpoints. There were no differences between the LMWH's except for cumulative flow at high doses. Conclusions: This study revealed no relevant differences between nadroparin and enoxaparin." . "Rau\u0161er, Petr" . "Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention"@en . "Hemostasis; Blood coagulation; Heparin; Low molecular weight heparins; Animal model"@en . "V" . "RIV/00216224:14110/10:00046981!RIV11-MSM-14110___" . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Vla\u0161\u00EDn, Michal" . "Introduction: The aim of the study was to compare the efficacy of standard unfractionated heparin (UFH) and low-molecular weight heparins (LMWH's). Methods: We modified a previously published rabbit model of arterial thrombosis prevention to compare UFH and two different doses of two LMWH fragments - nadroparin and enoxaparin. Thrombosis was triggered by vessel wall injury and critical stenosis. Blood flow monitored by a flow probe. The primary endpoints were: cumulative flow, time to occlusion and residual clot weight. Thirty six animals were split into 6 groups. Control groups were given saline or UFH and four more groups were used to compare LMWH's at 2 different doses. Results: In our study, all treatments were superior to the saline control group. UFH was inferior to both LMWH's for all primary endpoints. There were no differences between the LMWH's except for cumulative flow at high doses. Conclusions: This study revealed no relevant differences between nadroparin and enoxaparin."@en . . . . . . "Lexmaulov\u00E1, Leona" . "Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention" . "5"^^ . "Dvo\u0159\u00E1kov\u00E1, Martina" . . . "5"^^ . . "14110" . "Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention"@en .